aap Implantate AG: Capital increase in cash from authorized capital

As part of its measures to ensure corporate financing, aap Implantate AG, a specialist in biomedical implants for the musculo-skeletal organ system, has carried out a capital increase in cash from authorized capital. This partial utilization of authorized capital took the form of a subscription to stock to the value of EUR 200,000 at an issue price of EUR 1.90 per share. Subscribers included the company’s CEO, Mr. Uwe Ahrens. The company already has access to this additional liquidity. The share subscription will not be binding if completion of the capital increase has not been entered in the Commercial Register by September 30, 2003. The company’s capital stock would thereby increase by EUR 105,264 from the present EUR 4,764,265 to EUR 4,869,259.